Kim H - Search Results

1

The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis.

Kim H, Lee KK, Heo MH, Kim JY. Kim H, et al. Among authors: kim jy. Korean J Intern Med. 2019 Nov;34(6):1324-1332. doi: 10.3904/kjim.2018.051. Epub 2018 Oct 26. Korean J Intern Med. 2019. PMID: 30360020 Free PMC article.

2

Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer.

Kim H, Heo MH, Kim JY. Kim H, et al. Among authors: kim jy. BMC Gastroenterol. 2020 Jan 28;20(1):20. doi: 10.1186/s12876-020-1171-1. BMC Gastroenterol. 2020. PMID: 31992208 Free PMC article.

3

Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study.

Kim H, Lim M, Kim JY, Shin SJ, Cho YK, Cho CH. Kim H, et al. Among authors: kim jy. Diagnostics (Basel). 2020 Apr 23;10(4):249. doi: 10.3390/diagnostics10040249. Diagnostics (Basel). 2020. PMID: 32340330 Free PMC article.

4

Correction to: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer.

Kim H, Heo MH, Kim JY. Kim H, et al. Among authors: kim jy. BMC Gastroenterol. 2020 Jul 2;20(1):207. doi: 10.1186/s12876-020-01347-3. BMC Gastroenterol. 2020. PMID: 32615928 Free PMC article.

5

ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.

Kim H, Kim ST, Yoo KH, Hong JY, Park YS, Lim HY, Park JO. Kim H, et al. Among authors: kim st. In Vivo. 2021 Jan-Feb;35(1):499-505. doi: 10.21873/invivo.12284. In Vivo. 2021. PMID: 33402502 Free PMC article.

6

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.

Kim H, Kim J, Byeon S, Jang KT, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Kim H, et al. Among authors: kim st, kim j. Oncology. 2021;99(6):365-372. doi: 10.1159/000514404. Epub 2021 Mar 17. Oncology. 2021. PMID: 33730723

7

Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.

Kim H, Choi E, Heo MH, Kim JY, Park KU. Kim H, et al. Among authors: kim jy. Oncology. 2022;100(6):313-319. doi: 10.1159/000524476. Epub 2022 Apr 7. Oncology. 2022. PMID: 35390786

8

Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.

Kim H, Kim JY, Park KU. Kim H, et al. Among authors: kim jy. Oncology. 2023;101(1):41-48. doi: 10.1159/000527525. Epub 2022 Oct 18. Oncology. 2023. PMID: 36257294 Free article.

9

Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.

Kim H, Lim DH, Kwon YS, Kim MA, Park KU. Kim H, et al. Among authors: kim ma. Anticancer Res. 2023 May;43(5):2343-2349. doi: 10.21873/anticanres.16399. Anticancer Res. 2023. PMID: 37097676

10

Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.

Kim J, Byeon S, Kim H, Yeo JH, Hong JY, Lee J, Lim HY, Kang WK, Kim ST. Kim J, et al. Among authors: kim h, kim st. Target Oncol. 2020 Apr;15(2):203-209. doi: 10.1007/s11523-020-00713-1. Target Oncol. 2020. PMID: 32314267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101,320 results

Search Page

Filters